当前位置: 首页 » 论文全文
←返回首页
期刊信息:
《药学服务与研究》2019年, 第19卷, 第2期, 第114-117页
标题:
一例艰难梭菌菌血症的病例报告及文献分析
DOI:
10.5428/pcar20190209
作者:
1. 郑笑笑1(1.徐州市第一人民医院药学部 江苏徐州 221002 xiaoxiao-0912@163.com)
2. 徐圣秋1(1.徐州市第一人民医院药学部 江苏徐州 221002 )
3. 陈尔真2(2.上海交通大学医学院附属瑞金医院急诊重症监护室 上海 200025 chenerzhen@hotmail.com)
4. 何娟3(3.上海交通大学医学院附属瑞金医院药剂科 上海 200025 hejuanwin@126.com)
摘要:
摘要  目的:通过分析1例艰难梭菌血流感染治疗成功的案例,为艰难梭菌菌血症(Clostridium difficile bacteremia,CDB)优化治疗提供参考。方法:对1例CDB病人的临床表现、发病机制、高危因素和治疗方案进行分析,并结合相关文献分析CDB的临床特征。结果:该病例为结肠炎症伴慢性穿孔致艰难梭菌血流感染的68岁男性病人,使用万古霉素和甲硝唑抗感染治疗后痊愈。结论:CDB发生率低,死亡率高,早期合理抗感染治疗至关重要。
欢迎阅读《药学服务与研究》!您是该文第 47 位读者!
若需在您的论文中引用此文,请按以下格式著录参考文献:
中文著录格式 郑笑笑1,徐圣秋1,陈尔真2,何娟3. 一例艰难梭菌菌血症的病例报告及文献分析[J]. 药学服务与研究. 2019; 19(2): 114-117.
英文著录格式 ZHENG Xiaoxiao1,XU Shengqiu1,CHEN Erzhen2,HE Juan3. Clostridium difficile bacteremia:one case report and literature analysis[J]. Pharmaceutical Care and Research / yao xue fu wu yu yan jiu. 2019; 19(2): 114-117.
参考文献:
1. Mattila E,Arkkila P,Mattila P S,et al.Extraintestinal Clostridium difficile infections[J].Clin Infect Dis,2013,57(6):e148-e153.
2. Kaufman E,Liska D,Rubinshteyn V,et al.Clostridium difficile bacteremia[J].Surg Infect,2013,14(6):559-560.
3. Doufair M,Eckert C,Drieux L,et al.Clostridium difficile bacteremia:report of two cases in French hospitals and comprehensive review of the literature[J].IDCases,2017,8(1):54-62.
4. Lee N Y,Huang Y T,Hsueh P R,et al.Clostridium difficile bacteremia,Taiwan[J].Emerg Infect Dis,2010,16(8):1204-1210.
5. Naggie S,Frederick J,Pien B C,et al.Community-associated Clostridium difficile infection:experience of a veteran affairs medical center in southeastern USA[J].Infection,2010,38(4):297-300.
6. Libby D B,Bearman G.Bacteremia due to Clostridium difficile-review of the literature[J].Int J Infect Dis,2009,13(5):e305-e309.
7. Falcone M,Russo A,Iraci F,et al.Risk factors and outcomes for bloodstream infections secondary to Clostridium difficile infection[J].Antimicrob Agents Chemother,2016,60(1):252-257.
8. Wolf L E,Gorbach S L,Granowitz E V.Extraintestinal Clostridium difficile:10 years’ experience at a tertiary-care hospital[J].Mayo Clin Proc,1998,73(10):943-947.
9. 杨雪妹,吴允孚.艰难梭菌的生物学特性与实验室诊断[J].中国感染与化疗杂志,2013,13(3):232-234.
10. 杨雪妹,吴允孚.艰难梭菌感染的流行病学和诊治进展[J].中国感染与化疗杂志,2013,13(4):312-316.
11. Hagiya H,Kimura K,Ueda A,et al.Infective thoracic aortic aneurysm caused by Clostridium difficile after endovascular aortic repair[J].J Infect Chemother,2016,23(1):62-64.
12. Dauby N,Libois A,van Broeck J,et al.Fatal community-acquired ribotype 002 Clostridium difficile bacteremia[J].Anaerobe,2017,44:1-2.
13. Shah K,Brauch R,Cherabuddi K.Successful treatment of Clostridium difficile bacteremia with aortic mycotic aneurysm in a patient with prior endovascular aortic aneurysm repair[J].Case Rep Infect Dis,2017,8472930.
14. Cohen S H,Gerding D N,Johnson S,et al.Clinical practice guidelines for Clostridium difficile infection in adults:2010 update by the Society for Healthcare Epidemiology of America (SHEA) and the Infectious Diseases Society of America (IDSA)[J].Infect Contr Hosp Epidemiol,2010,31(5):431-455.
15. Chihara S,Shimizu R,Furukata S,et al.Oral vancomycin may have significant absorption in patients with Clostridium difficile colitis[J].Scand J Infect Dis,2011,43(2):149-150.
16. Rybak M,Lomaetro B,Rotschafer J C,et al.Therapeutic monitoring of vancomycin in adult patients:a consensus review of the American Society of Health System Pharmacists,the Infections Diseases Society of America,and the Society of Infections Diseases Pharmacists[J].Am J Health-Syst Pharm,2009,66(1):82-98.
17. Cornely O A,Miller M A,Louie T J,et al.Treatment of first recurrence of Clostridium difficile infection:fidaxomicin versus vancomycin[J].Clin Infect Dis,2012,55(Suppl 2):S154-S161.